NASDAQ:MDXG

MiMedx Group Competitors

$12.25
-0.15 (-1.21 %)
(As of 04/14/2021 12:28 PM ET)
Add
Compare
Today's Range
$12.06
Now: $12.25
$12.34
50-Day Range
$8.59
MA: $10.34
$12.72
52-Week Range
$3.30
Now: $12.25
$12.87
Volume5,641 shs
Average Volume569,119 shs
Market Capitalization$1.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

MiMedx Group (NASDAQ:MDXG) Vs. TNDM, NVRO, SWAV, ICUI, GKOS, and CMD

Should you be buying MDXG stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to MiMedx Group, including Tandem Diabetes Care (TNDM), Nevro (NVRO), ShockWave Medical (SWAV), ICU Medical (ICUI), Glaukos (GKOS), and Cantel Medical (CMD).

Tandem Diabetes Care (NASDAQ:TNDM) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Profitability

This table compares Tandem Diabetes Care and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-11.10%-10.98%-5.59%
MiMedx Group-37.28%-404.08%-58.81%

Volatility & Risk

Tandem Diabetes Care has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tandem Diabetes Care and MiMedx Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million14.96$-24,750,000.00($0.22)-394.09
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A

Tandem Diabetes Care has higher revenue and earnings than MiMedx Group.

Analyst Ratings

This is a breakdown of current recommendations for Tandem Diabetes Care and MiMedx Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care04902.69
MiMedx Group00103.00

Tandem Diabetes Care currently has a consensus target price of $115.9231, indicating a potential upside of 33.71%. MiMedx Group has a consensus target price of $20.00, indicating a potential upside of 63.27%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Tandem Diabetes Care.

Insider & Institutional Ownership

88.6% of Tandem Diabetes Care shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 6.0% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tandem Diabetes Care beats MiMedx Group on 8 of the 13 factors compared between the two stocks.

Nevro (NYSE:NVRO) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Nevro and MiMedx Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
MiMedx Group00103.00

Nevro presently has a consensus price target of $181.3846, suggesting a potential upside of 21.08%. MiMedx Group has a consensus price target of $20.00, suggesting a potential upside of 63.27%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Nevro.

Profitability

This table compares Nevro and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
MiMedx Group-37.28%-404.08%-58.81%

Risk & Volatility

Nevro has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Valuation and Earnings

This table compares Nevro and MiMedx Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million13.29$-103,690,000.00($3.37)-44.45
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A

MiMedx Group has lower revenue, but higher earnings than Nevro.

Insider & Institutional Ownership

4.0% of MiMedx Group shares are owned by institutional investors. 7.6% of Nevro shares are owned by company insiders. Comparatively, 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Nevro on 7 of the 13 factors compared between the two stocks.

MiMedx Group (NASDAQ:MDXG) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares MiMedx Group and ShockWave Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A
ShockWave Medical$42.93 million115.62$-51,110,000.00($2.14)-66.57

MiMedx Group has higher revenue and earnings than ShockWave Medical.

Profitability

This table compares MiMedx Group and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MiMedx Group-37.28%-404.08%-58.81%
ShockWave Medical-108.73%-30.28%-25.31%

Volatility & Risk

MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for MiMedx Group and ShockWave Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MiMedx Group00103.00
ShockWave Medical04202.33

MiMedx Group currently has a consensus target price of $20.00, suggesting a potential upside of 63.27%. ShockWave Medical has a consensus target price of $112.50, suggesting a potential downside of 21.02%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts clearly believe MiMedx Group is more favorable than ShockWave Medical.

Insider & Institutional Ownership

4.0% of MiMedx Group shares are owned by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by insiders. Comparatively, 15.3% of ShockWave Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MiMedx Group beats ShockWave Medical on 8 of the 13 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional & Insider Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 4.0% of MiMedx Group shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 19.8% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ICU Medical and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICU Medical6.43%9.73%7.70%
MiMedx Group-37.28%-404.08%-58.81%

Risk and Volatility

ICU Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ICU Medical and MiMedx Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICU Medical00203.00
MiMedx Group00103.00

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. MiMedx Group has a consensus target price of $20.00, suggesting a potential upside of 63.27%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than ICU Medical.

Earnings and Valuation

This table compares ICU Medical and MiMedx Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A

ICU Medical has higher revenue and earnings than MiMedx Group.

Summary

ICU Medical beats MiMedx Group on 8 of the 12 factors compared between the two stocks.

MiMedx Group (NASDAQ:MDXG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for MiMedx Group and Glaukos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MiMedx Group00103.00
Glaukos16102.00

MiMedx Group presently has a consensus price target of $20.00, suggesting a potential upside of 63.27%. Glaukos has a consensus price target of $66.3750, suggesting a potential downside of 21.44%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Glaukos.

Institutional and Insider Ownership

4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Comparatively, 8.7% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

MiMedx Group has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500.

Profitability

This table compares MiMedx Group and Glaukos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MiMedx Group-37.28%-404.08%-58.81%
Glaukos-33.61%-7.99%-5.87%

Earnings & Valuation

This table compares MiMedx Group and Glaukos' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A
Glaukos$236.98 million16.32$15.42 million($0.10)-844.90

Glaukos has lower revenue, but higher earnings than MiMedx Group.

MiMedx Group (NASDAQ:MDXG) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Profitability

This table compares MiMedx Group and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MiMedx Group-37.28%-404.08%-58.81%
Cantel Medical3.38%11.19%4.10%

Analyst Recommendations

This is a summary of current ratings and recommmendations for MiMedx Group and Cantel Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MiMedx Group00103.00
Cantel Medical12102.00

MiMedx Group currently has a consensus target price of $20.00, suggesting a potential upside of 63.27%. Cantel Medical has a consensus target price of $71.50, suggesting a potential downside of 16.19%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than Cantel Medical.

Insider and Institutional Ownership

4.0% of MiMedx Group shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 19.8% of MiMedx Group shares are held by company insiders. Comparatively, 10.7% of Cantel Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares MiMedx Group and Cantel Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$299.26 million4.55$-25,580,000.00N/AN/A
Cantel Medical$1.02 billion3.55$13.71 million$1.6551.70

Cantel Medical has higher revenue and earnings than MiMedx Group.

Risk & Volatility

MiMedx Group has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Summary

Cantel Medical beats MiMedx Group on 7 of the 12 factors compared between the two stocks.


MiMedx Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$86.70-1.5%$5.50 billion$362.30 million-107.04
Nevro logo
NVRO
Nevro
1.2$149.81-2.5%$5.06 billion$390.26 million-55.08News Coverage
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$142.45-0.7%$4.93 billion$42.93 million-70.52
ICU Medical logo
ICUI
ICU Medical
1.5$207.89-0.9%$4.37 billion$1.27 billion55.00Insider Selling
Glaukos logo
GKOS
Glaukos
0.9$84.49-1.8%$3.80 billion$236.98 million-51.21Analyst Upgrade
Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
1.3$85.31-0.4%$3.59 billion$1.02 billion101.56
NuVasive logo
NUVA
NuVasive
1.1$68.70-0.3%$3.52 billion$1.17 billion-312.27
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.78-1.3%$3.39 billion$994.85 million-116.56
AtriCure logo
ATRC
AtriCure
1.5$66.53-0.9%$3.01 billion$230.81 million-57.85Analyst Report
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$91.12-5.9%$2.50 billion$214.55 million-47.71Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$59.49-1.7%$2.43 billion$13.82 million-30.35
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$9.05-3.5%$1.82 billion$4.11 million-6.65
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.87-0.2%$1.75 billion$334.64 million94.54Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.26-2.5%$1.72 billion$63.35 million-42.02
Alphatec logo
ATEC
Alphatec
0.8$17.14-0.1%$1.63 billion$113.43 million-15.58Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.90-2.5%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.78-3.4%$1.47 billion$236.54 million-57.24
Atrion logo
ATRI
Atrion
1.1$647.72-0.4%$1.18 billion$155.07 million36.49
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$56.40-2.0%$1.08 billion$189.49 million-125.33
SI-BONE logo
SIBN
SI-BONE
1.2$33.11-0.4%$1.08 billion$67.30 million-20.69Increase in Short Interest
Cerus logo
CERS
Cerus
1.7$6.34-1.3%$1.05 billion$74.65 million-16.26News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.69-0.6%$1.03 billion$117.23 million53.43
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.46-0.8%$964.42 million$72.55 million-34.35
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.03-0.0%$916.43 million$264.16 million-5.38Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.75-0.1%$891.15 million$276.22 million-59.87
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.06-0.9%$847.99 million$459.95 million35.88
Surmodics logo
SRDX
Surmodics
1.3$57.42-0.1%$790.83 million$94.86 million717.75
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.30-0.2%$742.48 million$154.60 million-44.78
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.05-0.2%$679.37 million$123.86 million67.51
Intersect ENT logo
XENT
Intersect ENT
1.4$20.00-1.3%$652.07 million$109.14 million-10.47
Vapotherm logo
VAPO
Vapotherm
1.5$22.75-1.5%$595.63 million$48.10 million-10.83
SeaSpine logo
SPNE
SeaSpine
1.3$21.55-2.0%$589.95 million$159.08 million-12.90Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.07-1.6%$579.22 million$114.51 million-87.38Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.98-2.9%$556.70 millionN/A-9.68
Accuray logo
ARAY
Accuray
2.3$5.26-0.8%$484.93 million$382.93 million37.57News Coverage
iCAD logo
ICAD
iCAD
1.5$18.31-1.1%$451.02 million$31.34 million-19.27
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.74-0.1%$449.02 million$14.26 million-10.02Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.78-3.2%$415.73 million$11.22 million-47.23News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.20-1.2%$414.73 million$4.17 million-17.26News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.07-2.0%$400.19 million$24.95 million-27.48
PAVmed logo
PAVM
PAVmed
1.4$4.91-3.1%$392.51 millionN/A-6.46Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.50-0.4%$370.59 million$198.38 million24.75
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.29-0.9%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.11-2.8%$352.56 millionN/A-22.81
Neuronetics logo
STIM
Neuronetics
1.5$13.08-2.8%$322.94 million$62.66 million-7.79
Apyx Medical logo
APYX
Apyx Medical
1.0$9.51-1.4%$321.90 million$28.15 million-20.23Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57-1.5%$317.93 million$46.90 million27.94
IRadimed logo
IRMD
IRadimed
1.5$23.94-2.2%$301.25 million$38.52 million74.81News Coverage
Gap Up
DarioHealth logo
DRIO
DarioHealth
1.3$18.45-0.7%$285.89 million$7.56 million-2.31
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.